Pedro Tofani Saint’ana

Pedro Tofani Saint’ana

Auto-generated profile, based on publicly available information

Pedro Tofani Saint’ana

Hospital Moinhos de Vento, Porto Alegre, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
PVPedro Isaacsson Velho
Pedro Isaacsson Velho
DBDiogo Assed Bastos
Diogo Assed Bastos
PSPedro Tofani Saint’aNa
Pedro Tofani Saint’aNa
BRBrenda Rigatti
Brenda Rigatti
ECEmily Tonin. da Costa
Emily Tonin. da Costa
GCGilberto de Castro
Gilberto de Castro
Purpose: Despite the success of immune checkpoint inhibitors (ICI) across various cancers, their efficacy in metastatic castration-resistant prostate cancer (mCRPC) is modest, except for a subset of patients who experience significant, yet unpredictable, benefits. DNA repair defects (DRD) are associated with higher neoantigen load, which may predict response. Our study explored the potential of DRD for enhanced responsiveness to the ICI nivolumab. Patients and Methods: We conducted a phase II, multicenter, single-arm trial evaluating nivolumab in patients with mCRPC with prior docetaxel therapy. The DRD were assessed using ctDNA. The primary endpoint was PSA50 response. Secondary endpoints included the objective response rate, radiographic progression-free survival (rPFS), and overall survival. Also, exploratory comprehensive genomic profiling was performed via whole-exome sequencing of tumor samples and matched normal tissues, alongside PD-L1 expression evaluation. Results: Among the 38 enrolled patients, DRD was identifiable in 30.5% (11/36) through ctDNA and/or whole-exome sequencing analyses. The overall PSA50 response rate was 10.5% (4/38). The PSA50 and objective response rates did not significantly differ between patients with and without DRD (18.2% vs. 8%; P = 0.57 and 50% vs. 17.6%; P = 0.27, respectively). The median PSA-PFS (1.9 vs. 2.8 months; P = 0.52) and rPFS (3.4 vs. 5.5 months; P = 0.7) were not statistically different between patients with and without DRD. Grade ≥ 3 adverse events were reported in 47.3% of participants. Conclusions: Nivolumab has clinical activity in a subset of patients with mCRPC; however, DRD does not predict response. These results highlight the necessity of identifying new biomarkers to more accurately determine patients with mCRPC who might respond to ICIs.

1 January 2024 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
DADenise Ferreira Silva Alves
Denise Ferreira Silva Alves
DRDaniela Dornelles Rosa
Daniela Dornelles Rosa
LFLuciane Borelli Finatto
Luciane Borelli Finatto
BRBrenda Rigatti
Brenda Rigatti
PAPedro Tofani Sant' Anna
Pedro Tofani Sant' Anna
The objective of this study was to evaluate the quality of life of consecutive patients undergoing radiotherapy during the coronavirus disease 2019 pandemic at a private hospital in Southern Brazil from September 2020 to September 2021.

2 December 2024
Verified
Other
Open access
PVPedro Isaacsson Velho
Pedro Isaacsson Velho
DBDiogo Assed Bastos
Diogo Assed Bastos
PSPedro Tofani Saint’ana
Pedro Tofani Saint’ana
BRBrenda Rigatti
Brenda Rigatti
ECEmily Tonin da Costa
Emily Tonin da Costa
GCGilberto de Castro
Gilberto de Castro
Supplementary Figure 2A: KM curve of PSA-PFS by TMB

2 December 2024
Verified
Other
Open access
PVPedro Isaacsson Velho
Pedro Isaacsson Velho
DBDiogo Assed Bastos
Diogo Assed Bastos
PSPedro Tofani Saint’aNa
Pedro Tofani Saint’aNa
BRBrenda Rigatti
Brenda Rigatti
ECEmily Tonin da Costa
Emily Tonin da Costa
GCGilberto de Castro
Gilberto de Castro
Supplementary Figure 4B: KM curve of rPFS in patients with and without PD-L1 expression.

2 December 2024
Verified
Other
Open access
PVPedro Isaacsson Velho
Pedro Isaacsson Velho
DBDiogo Assed Bastos
Diogo Assed Bastos
PSPedro Tofani Saint’ana
Pedro Tofani Saint’ana
BRBrenda Rigatti
Brenda Rigatti
ECEmily Tonin da Costa
Emily Tonin da Costa
GCGilberto de Castro
Gilberto de Castro
Representativeness of Study Participants

2 December 2024
Verified
Other
Open access
PVPedro Isaacsson Velho
Pedro Isaacsson Velho
DBDiogo Assed Bastos
Diogo Assed Bastos
PSPedro Tofani Saint’ana
Pedro Tofani Saint’ana
BRBrenda Rigatti
Brenda Rigatti
ECEmily Tonin da Costa
Emily Tonin da Costa
GCGilberto de Castro
Gilberto de Castro
Supplementary Figure 2C: KM curve of OS by TMB